Actions Taken by FDA Center for Veterinary Medicine

The following corrections or additions to the January 15, 1998 list weremade in July, 1998

New Approvals

ANADANumber: 200-202

Pioneer Product: 140-439

Trade Name: Phoenectin™ Liquid for Horses

Ingredients: Ivermectin

Sponsor: Phoenix Scientific, Inc.

Approval Date: 06/05/98 Status: Prescription only

Route: Oral Species: Equine

Liquid (solution) Drug Form: 10 mg/mLConcentration:

Indications: For the treatment and control of largestrongyles (adult) (Strongylus equinus), (adult andarterial larval

stages) (Strongylus vulgaris), (adult and migrating tissue stages) (Strongylus endentatus) (adult) (*Triodontophorus* spp.); small strongyles (adult and fourth stagelarvae) (*Cyathostomum* spp. Cylicocyclus spp., Cylicodontophorus spp.Cylicostephanus spp.); pinworms (adult and fourth stagelarvae) (Oxyuris equi); ascarids (third- and fourth-stagelarvae and adults) (Parascaris equorum); hairworms (adult) (Trichostongylusaxei); large mouth stomach worms (adult) (Habronemamuscae); stomach bots (oral and gastric stages) (Gastrophilus spp.); lungworms (adults and fourth stage larvae) (Dictyocaulusarnfieldi); intestinal threadworms (adults) (Strongyloides westeri); summer sores caused

by Habronema and Draschia spp. cutaneous third stage larvae; and dermatitis caused by

neckthreadworm microfilariae (Onchocerca spp.).

21CFR 520.1195

ANADA Number: 200-246

Pioneer Product: 091-739 Trade Name: Anthelban V Ingredients: Pyrantel pamoate Phoenix Scientific, Inc. Sponsor:

Approval Date: 06/18/98

Status: Over-the-counter

Route: Oral Species: Equine

Drug Form: Liquid (suspension)

Concentration: 50 mg/mL pyrantel base as pyrantel pamoate

Indications: For the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S.

equinus); pinworms (Oxyuris equi); large roundworms (Parascarisequorum); and small strongyles in

horses and ponies.

21CFR 520.2043

NADA Number: 141-100

DECCOX®,BMD®, 3-NITRO® Trade Name:

Ingredients: Decoquinate, bacitracin methylene disalicylate, roxarsone

Alpharma, Inc. Sponsor: Approval Date: 06/02/98 Status: Over-the-counter Route: Oral

Species: Avian (broiler chickens)

Type A medicated articles to make Type C medicated feed Drug Form:

Concentration: Decoquinate 27.2g/lb (6%); bacitracin methylenedisalicylate 10, 25, 30, 40, 50, 60, or 75 g/lb; roxarsone

45.4, 90, or 227g/lb

Actions Taken by FDA Center for Veterinary Medicine

NADANumber: 141-100, con't

> Indications: For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. mivati, E. acervulina,

> > E.maxima, and E. brunetti, as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin, and for increased rate of weight gain,

improved feed efficiency, and improvedpigmentation in broiler chickens.

21CFR 556.170: Decoquinate: 2ppm in tissues other thanskeletal muscle and 1 ppm in skeletal muscle Tolerance:

21CFR 556.70: Bacitracin: 0.5 ppm negligible residue in uncookededible tissues of chickens

21CFR 556.60: Arsenic residues (from roxarsone): 0.5 ppm inuncooked edible muscle and 2 ppm in

uncooked edible by-products of chickens.

Withdrawal: 5 days

This NADA provides for the combined use of three approved Type Amedicated articles in the manufacture of Type C medicated feeds, ratherthan a premix incorporating all three of these compounds.

21CFR 558.76, 558.195, and 558.530

NADANumber: 141-085

ZOAMIX®,BMD® Trade Name:

Ingredients: Zoalene, bacitracin methylene disalicylate

Sponsor: Alpharma, Inc. Approval Date: 06/03/98 Status: Over-the-counter

Route: Oral

Species: Avian (turkey)

Drug Form: Type A medicated articles to make Type C medicated feed

Concentration: Zoalene 113.5 g/lb (25%); bacitracin methylenedisalicylate 10, 25, 30, 40, 50, 60, or 75 g/lb

Indications: For the prevention and control of coccidiosis, for increased weight gain, and improved feed efficiency

ingrowing turkeys.

Tolerance: 21 CFR 556.770: Zoalene (and its metabolite3-amino-5-nitro-o-toluamide): 3 ppm in uncooked muscle

tissue and liver.

21CFR 556.70: Bacitracin: 0.5 ppm negligible residue in uncookededible tissues of turkeys

Withdrawal: Zero days

This NADA provides for the combined use of two approved Type Amedicated articles in the manufacture of Type C medicated feeds, ratherthan a premix incorporating both of these compounds.

21CFR 558.76and 558.680

NADA Number: 141-088

HISTOSTAT®, BMD® Trade Name:

Nitarsone, Bacitracin methylene disalicylate Ingredients:

Sponsor: Alpharma, Inc. Approval Date: 06/17/98 Status: Over-the-counter

Route: Oral

Species: Avian (turkey)

Drug Form: Type A medicated articles to make Type C medicated feed

Nitarsone 227g/lb; bacitracin methylenedisalycilate 10, 25, 30, 40, 50, 60, 75 g/lb Concentration:

Indications: As an aid in the prevention of blackhead, for increased weight gain, and improved feed efficiency

ingrowing turkeys.

Tolerance: 21CFR 556.70: Bacitracin: 0.5 ppm negligible residuein uncooked edible tissues of turkeys

21CFR 556.60: Arsenic residues: 0.5 ppm in uncooked ediblemuscle and 2 ppm in uncooked edible by-

products of turkeys.

Withdrawal: 5 days

Actions Taken byFDA Center for Veterinary Medicine

NADANumber: 141-088, con't

This NADA provides for the combined use of two approved Type A medicatedarticles in the manufacture of Type C medicated feeds, rather than a premixincorporating both of these compounds.

21CFR 558.76and 558.369

Supplemental Approvals

NADA Number: 046-666

Trade Name: Procaine G Penicillin 50% Type A Medicated Article

Ingredients: Procaine G Penicillin Sponsor: Alpharma, Inc. Approval Date: 04/10/98 Status: Over-the-counter

Route: Oral

Species: Porcine, Avian (chickens, pheasants, quail, and turkeys)
Drug Form: Type A medicated article to make Type C medicated feeds

Concentration: 50%

Indications: For increased rate of weight gain and improved feedefficiency.

Tolerance: 21CFR 556.510 (a) Zero in the uncooked edible tissues of chickens, pheasants, quail, and swine.

(b) 0.01 ppm in the uncooked edible tissues of turkeys.

Withdrawal: Zero days

This supplemental application provides for compliance with the conclusions of the National Academy of Science/National Research Council(NAS/NRC) evaluation of penicillin-containing Type A Medicated Articles.

21CFR 558.460

NADANumber: 046-668

Trade Name: Procaine G Penicillin 50% Type A Medicated Article

Ingredients: Procaine G Penicillin

Sponsor: Pfizer, Inc.
Approval Date: 04/10/98
Status: Over-the-counter

Route: Oral

Species: Porcine, Avian (chickens, pheasants, quail, and turkeys)
Drug Form: Type A medicated articles to make Type C medicated feeds

Concentration: 60 or 136 grams/ton

Indications: For increased rate of weight gain and improved feedefficiency.

Tolerance: 21CFR 556.510 (a) Zero in the uncooked edible tissues of chickens, pheasants, quail, and swine.

(b) 0.01 ppm in the uncooked edible tissues of turkeys.

Withdrawal: Zero days

This supplemental application provides for compliance with the conclusions of the National Academy of Science/National Research Council(NAS/NRC) evaluation of penicillin-containing Type A MedicatedArticles.

21CFR 558.460

NADA Number: 140-989

Trade Name: Parasite-S Ingredients: Formalin

Sponsor: Western Chemical, Inc.

Approval Date: 06/18/98

Status: Over-the-counter

Route: In the environmental water

Actions Taken byFDA Center for Veterinary Medicine

NADANumber: 140-989, con't

Species: Fish (all finfish including their eggs), penaeid shrimp

Drug Form: Liquid (solution)

Concentration: 37% w/w formaldehyde gas in water

Indications: For the control of external protozoa (Chilodonella spp., Costia spp., Epistylis spp., Ichthyophthirius

spp., Scyphidia spp., and Trichodina spp.) and the monogenea parasites (Cleidodiscus spp., Dactylogyrus spp., and Gyrodactylus spp.) on all finfish; the control of fungi of the family

Saprolegniaceaeon all finfish eggs; and the control of external protozoan parasites(Bodo spp., Epistylis

spp., and Zoothamnium spp.) on peneaid shrimp.

This supplemental application provides for the expansion of indications as cited above.

21CFR 529.1030

NADANumber: 065-470

Trade Name: BMD® Soluble

Ingredients: Bacitracin methylene disalicylate

Sponsor: Alpharma, Inc.
Approval Date: 05/27/98
Status: Over-the-counter
Route: Oral (drinking water)
Species: Avian (quail)

Species: Avian (quail)
Drug Form: Powder

Concentration: Each 4.1 oz packet contains 51.2 g bacitracin activityfrom bacitracin methylene disalicylate equivalent

to 200 g/lb bacitracin.

Indications: For the prevention of ulcerative enteritis ingrowing quail due to *Clostridium colinum* susceptible

tobacitracin methylene disalicylate.

Tolerance: 21 CFR 556.70: The tolerance for residues ofbacitracin in uncooked tissues of chickens, turkeys, and

quail has beenestablished as 0.5 ppm.

Withdrawal: Not required.

This supplemental application provides for the addition of a newspecies, growing quail, to be added to the previously approved product.

21CFR 520.154a

NADA Number: 101-479

Trade Name: Banamine® InjectableSolution

Ingredients: Flunixin meglumine

Sponsor: Schering-Plough Animal Health Corp.

Approval Date: 05/06/98 Status: Prescription only Route: Intravenous

Species: Bovine (beef cattle and non-lactating dairy cattle)

Drug Form: Liquid (solution)
Concentration: 50 mg/mL

Indications: For the control of pyrexia associated with bovinerespiratory disease and endotoxemia, and for the

control of inflammation inendotoxemia.

Tolerance: 21 CFR 556.286: Acceptable daily intake (ADI) is 0.72micrograms/kg/day. A tolerance is established

for parent flunixin freeacid of 0.125 ppm in liver (target tissue) and 0.025 ppm in muscle.

Withdrawal: 4 days Exclusivity: 3 years

This supplemental application provides for an additional species, cattle, to be added to the previously approved product.

21CFR 522.970 and 556.286

Actions Taken byFDA Center for Veterinary Medicine

NADANumber: 046-592

Trade Name: BMD®

Ingredients: Bacitracin methylene disalicylate

Sponsor: Alpharma, Inc.
Approval Date: 06/22/98
Status: Over-the-counter

Route: Oral

Species: Avian (replacement chickens)

Drug Form: Type A medicated article to make Type C medicated feeds

Concentration: 10, 25, 30, 40, 50, 60, or 75 g/lb

Indications: As an aid in the prevention and control of necroticenteritis caused or complicated by *Clostridium* spp.

orother organisms susceptible to bacitracin methylene disalicylate.

Tolerance: 21CFR 556.70: Bacitracin: 0.5 ppm negligible residue in uncooked edibletissues of chickens.

This supplemental application provides for the addition of a class,replacement chickens, to be added to the previously approved product.

21CFR 558.76

Change of Sponsor

NADA Numbers: 091-818 & 094-170

From: Danbury Pharmacal, Inc. To: Phoenix Scientific, Inc. 3915 South 48th St. Terrace

P.O. Box 6457

St. Joseph, MO 64506-0457 Drug labeler code: 059130

Suitability Petition Action

Number: 98P-0232/CP1 Sponsor: Virbac, Inc.

Petition: Request permission to file an ANADA for ageneric new animal drug miconazole nitrate which differs

from the pioneerproduct, Conofite® Lotion 1%, Schering-Plough Animal Health Corporation, NADA 095-184, by the following characteristics: Miconazole 2% is formulated as a leave-on conditioner

and Conofite® Lotion 1% is formulated as a topical lotion and a different strength.

Action: Denied on 7/08/98.

Number: 98P-0580/CP1

Sponsor: Delmarva Laboratories, Inc.

Petition: Request permission to file an ANADA for ageneric new animal drug clindamycin hydrochloride which

differs from thepioneer product, Antirobe® Capsules, Pharmacia & Upjohn Co., NADA 120-161, by the

following characteristics: Clindamycin hydrochloride generic is a tablet and Antirobe® is a capsule.

Action: Filed on 7/16/98.